

Onyx*Changing the way cancer is treated***RECEIVED
CENTRAL FAX CENTER****JUL 10 2008**

ONYX PHARMACEUTICALS, INC.
2100 POWELL STREET
EMERYVILLE, CA 94608
www.onyx-pharm.com
Tel. 510.597-6500
Fax 510.597-6600

FACSIMILE TRANSMITTAL FORM

Date: 10 July 2008

To: Commissioner for Patents
United States Patent and Trademark
Office **Fax:** 1-571-273-8300

From: Gregory J. Giotto **Phone:** (510) 597-6502
Registration No. 32,028 **Fax:** (510) 597-6600

Re: U.S. Patent Application Serial No. 10/669,768 (Onyx Reference No. Onyx 1047.DIV)

Number Of Pages Including Cover Sheet: 4 (Four pages)

Message

THE ATTACHED DOCUMENTS ARE TO BE
MADE OF OFFICIAL RECORD

Transmitted herewith for filing in the above-referenced application are the following documents:


1. Transmittal;
2. Notification of Change from Small Entity to Large Entity Status and
3. Certificates of Transmission by Facsimile.

WARNING: This facsimile message and accompanying documents are intended only for the use of the addressee indicated above. Information that is privileged or otherwise confidential may be contained therein. If you are not the intended recipient, you are hereby notified that any dissemination, copying, review or use of this message, documents or information contained therein is strictly prohibited. If you have received this message in error, please notify us immediately by telephone or facsimile and mail the original to us at the above address. Thank you.

RECEIVED
CENTRAL FAX CENTER

JUL 10 2008

Onyx Dkt No. 1047.DIV
USSN: 10/669,768
PATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)		
I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.		
Signature	 Ann S. Chihak Poff	07/10/08 Date of Transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	
In Re Application of: Shen, Y.J., et al.	Confirmation No.: 8135
Serial No.: 10/669,768	Art Unit: 1633
Filing Date: 24 Sep 2003	Examiner: Marvich, Maria
Title: ADENOVIRUS E1B-55K SINGLE AMINO ACID MUTANTS AND METHODS OF USE	

TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-referenced application are the following documents:

1. Transmittal;
2. Notification of Change from Small Entity to Large Entity Status;
3. Certificates of Transmission by Facsimile.

Authorization to Charge Deposit Account:

JUL 10 2008 3:17PM

ONYX PHARMACEUTICALS

RECEIVED
CENTRAL FAX CENTER

NO. 786 P. 3

JUL 10 2008

Onyx Dkt No. 1047.DIV
USSN: 10/669,768
PATENT

No additional fees are believed due. However, the Commissioner is hereby authorized to charge to Deposit Account No. 15-0615 any fees (please reference **ONYX 1047.DIV**) under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Dated: 7/10/08

By : Gregory Gietta

Gregory Gietta, Ph.D., Esq.
Registration No. 32,028
Attorney for Applicant
ONYX Pharmaceuticals, Inc.

ONYX Pharmaceuticals, Inc.
2100 Powell Street
Emeryville, CA 94608
Phone: (510) 597-6502
Facsimile: (510) 597-6610

JUL 10 2008 3:17PM

ONYX PHARMACEUTICALS

NO. 786 P. 4

RECEIVED
CENTRAL FAX CENTER

JUL 10 2008

Onyx Dkt No. 1047.DIV
USSN: 10/669,768
PATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.

Signature Ann S. Chihak Poff Date of Transmittal 07/10/08

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Shen, Y.J., et al.	Confirmation No.: 8135
Serial No.: 10/669,768	Art Unit: 1633
Filing Date: 24 Sep 2003	Examiner: Marvich, Maria
Title: ADENOVIRUS E1B-55K SINGLE AMINO ACID MUTANTS AND METHODS OF USE	

Notification of Change from Small Entity to Large Entity Status

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant 37 C.F.R. §1.27(g)(2), the status of the above-identified application should be changed from SMALL ENTITY status to LARGE ENTITY status.

No fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 15-0615 (please reference **ONYX 1047.DIV**) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Date:

7/10/08

By:

Gregory L. Giotta
Gregory L. Giotta, Ph.D., Esq.
Registration No. 32,028
Attorney for Applicant
Onyx Pharmaceuticals, Inc.